Background: Tumor associated macrophages (TAMs) and CXC chemokine receptor 4 (CXCR4) have emerged as potential biomarkers in various human cancers. The aims of this study were to investigate the clinical characteristics of anaplastic thyroid cancer (ATC) patients according to the TAM numbers in the tumor tissue, and to evaluate the associations between CXCR4 expressions and macrophage densities in ATC tumor microenvironment. Methods: Total 14 ATC samples from thyroid tissue microarray were used. Immunohistochemical staining was performed using anti-CD163 and anti-CXCR4 antibodies. According to the immunoreactivity of CD163, all subjects were divided into two groups: low-CD163 (n=8) and high-CD163 (n=6) groups. Results: The mean diagnostic age was 65±7 years and the median tumor size was 4.3 cm, ranging 2.5 to 15 cm. Clinicopathological characteristics were not significantly different between low-CD163 and high-CD163 groups, while age of diagnosis was younger in high-CD163 group than that of low-CD163 group with marginal significance (56.9±5.5 years vs. 67.5±6.8 years, P=0.09). However, overall survival was significantly reduced in high-CD163 group (5.5 months [range, 1 to 10]) compared with low-CD163 groups (8.8 months [range, 6 to 121); log-rank test, P=0.0443). Moreover, high-CD163 group showed strong CXCR4 expressions in both cancer and stromal compartments, while low-CD163 group showed relatively weak, stromal-dominant CXCR4 expressions. Additionally, CD163 and CXCR4 expressions showed a strong positive correlation (γ 2 =0.432, P=0.013).
INTRODUCTION
Anaplastic thyroid cancer (ATC) is the most virulent and aggressive cancer in human solid cancers, showing extremely short survival outcomes [1] . The median survival time ranges from 2.5 to 6 months, and the 5-year survival rate is 0% to 14% [2, 3] . Although ATC accounts for only 2% to 5% of all thyroid cancers, it contributes more than 50% of the mortality associated with thyroid cancers [4, 5] . When ATC is diagnosed initially, regional or distance spread is apparent in 90% of cases [6] . Fifteen percent to 50% of patients are found to have metastatic lesions at the time of diagnosis, most frequently in the lungs or bone [6] [7] [8] [9] . Although treatments of ATC with surgery, radiotherapy, and chemotherapy, alone or in combination, are conducted in many cases, there are little or no effect on patient's survival [10] .
Recently, several studies demonstrated that macrophage densities in tumor microenvironment, especially M2-macrophages, were related to the poor clinical outcomes. Macrophages constitute a major type of stromal cells in tumor microenvironment. Macrophages undergo two different polarization states. In contrast to M1 macrophages, which play a role in microbicidal and tumorcidal, M2 macrophages perform immunosuppression and facilitate tumor suppression [11, 12] . The tumor associated macrophages (TAMs) including M2 macrophages play a key role during tumor progression and TAMs emerge as a potentially useful prognostic marker [13] . Several studies demonstrated that the high density of TAMs in cancer tissues was associated with advanced stage of cancers or poor clinical outcomes in various human cancers in such as lungs, liver, and thyroid. Recently, there were several efforts to inhibit TAMs recruitments into the tumor tissues as therapeutic strategies for cancer treatment.
Chemokines are small secretory proteins that were reported to not only regulate some important feature of cancer cells, but are also involved in the regulation of tumor angiogenesis and leukocyte recruitment [14] . Especially, CXC chemokine receptor 4 (CXCR4) is one of the most important chemokine receptors for cancer cell. CXCR4 is expressed in epithelial cancer cells and has a critical role in migration and metastasis [15, 16] . Lines of evidence demonstrated that overexpression of CXCR4 is a reliable indicator of metastatic potential or aggressive behavior in thyroid cancer. Additionally, CXCR4 has been shown to play a role constructing tumor microenvironment by facilitating recruitment of endothelial cells or macrophages.
The aims of this study were to investigate the clinical characteristics of ATC patients according to the TAM numbers in the tumor tissue, and to evaluate the associations between CXCR4 expressions and macrophage densities in ATC tumor microenvironment.
METHODS

Study subjects and construction of tissue microarrays
Thyroid tissue microarrays were constructed as previously reported [17] . Table 1 shows the clinical characteristics of 14 ATC patients (11 women and three men). The mean diagnostic age was 65± 7 years. The median tumor size was 4.3 cm ranging 2.5 to 15 cm and half of them had distant metastasis including lungs and liver at the time of diagnosis. Adjuvant therapy was conducted 10 of 14 patients, nine patients underwent external beam radiation therapy and one patient underwent concomitant chemotherapy and radiotherapy. The median overall survival was 7 months (range, 1 to 121) and all patients eventually died.
RESULTS
Clinicopathologic characteristics of ATC patients according to CD163-positive macrophage densities
Comparisons of clinical characteristics and survivals between low and high CD163-positive TAM density groups
To evaluate the association between CD163-positive TAM density and clinical characteristics in human ATC, we performed immunohistochemical staining using anti-CD163 antibody and divided into two groups according to the CD163 immunoreactivities. On the basis of the median percentage of positively stained nuclear area (47.2%), eight patients belong to the low expression group and six patients to the high expression group. Because of the limited sample size, clinical characteristics were not significantly different between groups (Table  2) . However, the mean diagnostic age was younger in high expression group than low expression group with marginal significance (56.9±5.5 years vs. 67.5±6.8 years, P=0.09). The median tumor size was 4.0 cm (range, 3.5 to 5.0) in low expression group and 5.3 cm (range, 2.5 to 15.0) in high expression group. Distant metastasis was observed in three of eight patients in low expression group and four of six patients in high expression group. Interestingly, survival analysis using log-rank test showed significant difference between groups (log-rank test, z=2.01, P=0.044) (Fig. 1) . The median overall survival was 5.5 months (range, 1 to 10) in low group and 8.8 months (range, 6 to 121) in high group (Table 2) . 
CXCR4 expressions according to the CD163-positive TAM densities in ATC and their relationship with
To further characterize TAMs in the ATC tumor microenvironment, CXCR4, a representative chemotactic signaling molecule, was stained. Fig. 2A showed representative images of CXCR4 staining in CD163-low or -high expression groups. Four patients from high expression group (n=6) showed both cancer and stromal compartments expressions of CXCR4, while all low expression group (n=8) showed stromal-dominant expressions of CXCR4, especially at perivascular area (Table 2) . Additionally, regression analysis showed that the densities of CD163 and CXCR4 showed positive correlations (γ 2 =0.432, P=0.013) (Fig. 2B) .
DISCUSSION
The present study demonstrated that high-CD163 group was significantly associated with poor overall survival in human ATC. It also showed younger diagnostic age and, larger tumor size compared to the low-CD163 group, while statistical sig- www.e-enm.org 473 nificance was not obtained because of the small sample size. CD163 and CXCR4 expression showed strong positive correlations in ATC tissues. In addition, CXCR4 staining in high-CD163 group showed both cancer and stromal compartments expressions, whereas all low expression patients showed stromal-dominant expressions of CXCR4.
In the previous studies, high density of TAMs is present in the more advanced stage of cancers that have poor prognosis, such as beast, lung, thyroid, and bladder cancers [19] [20] [21] [22] . Especially in thyroid cancer, Ryder et al. [23] reported that an increased density of TAMs was associated with tumor progression in advanced thyroid cancers. Qing et al. [24] found that overall density of TAMs was significantly higher in papillary thyroid cancer than benign lesions and positive associated with lymph node metastasis and TNM stage. Consistent to the previous studies, even with the limited sample size, the present study demonstrated that the high density of TAMs was associated with a shorter overall survival with in the most dedifferentiated pathologic subtype of thyroid cancer, ATC, compared to the previous studies.
ATC is one of the most aggressive human cancers with poor survival [25] . In previous study, Jung et al. [26] reported that CD163-positive macrophage density and 5-year survival rate had inverse correlations in 14 different types of human cancers, including lung, liver, pancreas, and thyroid, and ATC had the highest CD163-positive macrophages density with the lowest survival rate. Therefore, TAMs might be a potential therapeutic target for cancer treatment strategy in ATC. Indeed, several different experimental approaches have been tried for targeting TAMs: (1) inducing TAMs apoptosis using clodronate loaded liposome [27, 28] or zoledronic acid [29, 30] ; (2) inhibiting monocyte differentiation into M2-macrophages using colony stimulating factor 1 receptor inhibitor [31] ; and (3) stimulating repolarization into M1-macrophages using pantoprazole [32] or IL-12 [33] . Recently, Passaro et al. [34] demonstrated that oncolytic adenovirus dl922-947 reduced tumor growth and induced repolarization of TAMs into cytotoxic M1-marophages. However, whether TAMs infiltrations directly contribute to tumor growth or invasiveness or not is still elusive, and there are few studies about the characteristics of TAMs in ATC.
In order to evaluate whether TAMs, especially M2-macrophages, were accumulated in tumor microenvironments or not, we performed immunohistochemical staining using an anti-CD163 antibody, a specific maker for M2-macrophages [35] . Interestingly, in this study, CXCR4 expression was higher in the high CD163-positive TAM density group showing the co-expressions at both cancer and stromal compartments. On the other hand, low CD163-positive TAM density group showed stromal-dominant expressions of CXCR4. Since the abundance of CXCR4-positive cancer cells reflected relatively higher concentrations of chemokine 12 (CXCL12) at that microenvironment, it is reasonable to deduce that these CXCL12-rich environment enhanced macrophage infiltrations and M2-macrophages polarization. A study of breast cancer suggested that the high level of CXCL12 has led to enhance macrophages density in tumor parenchyma [36] . However, we did not evaluate the CXCL12 status in this study. Further study is needed to validate it.
One of the limitations of this study is that we cannot reveal the cellular origin of the stromal expression of CXCR4. CXCR4 is widely expressed in various cells including most leukocytes, macrophages, mesenchymal stromal cells, and endothelial cells [37] [38] [39] [40] , since CD163 and CXCR4 expression had a positive correlations, we could postulate that a part of CXCR4-positive stromal compartments were macrophages, or CXCR4-positive stromal compartments contributed to macrophages recruitment. Further experimental study is needed to reveal the causal relationship and the concrete cellular interactions.
In conclusion, high density of CD163-positive TAMs showed poor overall survival with aggressive clinical characteristics in ATC, suggesting the potential of TAMs as a prognostic biomarker for ATC. Furthermore, CXCR4 expression was significantly correlated with CD163-positive TAM densities, which suggest the possible role of CXCR4 in TAM recruitments. To validate the potentials of CXCR4 and TAMs as therapeutic targets of ATC treatment, further studies are needed to understand the molecular mechanisms of TAMs recruitment in relationship with CXCR4.
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